MYGN
Myriad Genetics, Inc.
Diagnostics & Research · Healthcare · United States
3.17
close · 2026-08-13
value
77
cheaper than peers77
quality
12
stronger fundamentals12
ranked against
Diagnostics & Research
value
quality
28 peers
Value inputs
| measure | company | vs peers |
| price to sales | 0.91× | 98 |
| price to book | 1.00× | 94 |
| forward P/E | 35.54× | 18 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 32.8% | 71 |
| operating margin | -21.4% | 24 |
| return on equity | -23.5% | 21 |
| revenue growth | -20.8% | 5 |
4 of 4 measures available
Facts
| market cap | $303M |
| free cash flow | -$46.1M |
| employees | 2,700 |
| first trade | 1995-10-06 |
| next earnings | 2026-07-30 |
| fundamentals updated | 2026-07-30 |